Molecular Oncology
Volume 3, Issue 3 , Pages 214-219 , June 2009

Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution

  • Wenjing Zhou

      Affiliations

    • Department of Surgical Sciences, Uppsala University, Uppsala SE 75105, Sweden
    • These two authors contributed equally to this work.
    • ,
  • Aslaug A. Muggerud

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Montebello, 0310 Oslo, Norway
    • Faculty of Medicine, Division The Norwegian Radium Hospital, University of Oslo, 0316 Oslo, Norway
    • These two authors contributed equally to this work.
    • ,
  • Phuong Vu

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Montebello, 0310 Oslo, Norway
    • ,
  • Eldri U. Due

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Montebello, 0310 Oslo, Norway
    • ,
  • Therese Sørlie

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Montebello, 0310 Oslo, Norway
    • Biomedical Research Group, Department of Bioinformatics, University of Oslo, 0316 Oslo, Norway
    • ,
  • Anne-Lise Børresen-Dale

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Montebello, 0310 Oslo, Norway
    • Faculty of Medicine, Division The Norwegian Radium Hospital, University of Oslo, 0316 Oslo, Norway
    • ,
  • Fredrik Wärnberg

      Affiliations

    • Department of Surgical Sciences, Uppsala University, Uppsala SE 75105, Sweden
    • ,
  • Anita Langerød

      Affiliations

    • Department of Genetics, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Montebello, 0310 Oslo, Norway
    • Corresponding Author InformationCorresponding author. Tel.: +47 22934424.

Received 3 February 2009 ,Accepted 23 March 2009.

References 

  1. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 1996;2(7):811–814
  2. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr. Relat. Cancer. 2001;8(1):47–61
  3. Borresen-Dale AL. TP53 and breast cancer. Hum. Mutat. 2003;21(3):292–300
  4. Borresen AL, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, et al TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer. 1995;14(1):71–75
  5. Claus EB, Stowe M, Carter D. Breast carcinoma in situ: risk factors and screening patterns. J. Natl. Cancer Inst. 2001;93(23):1811–1817
  6. D'Assoro AB, Busby R, Acu ID, Quatraro C, Reinholz MM, Farrugia DJ, et al Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts. Oncogene. 2008;
  7. Done SJ, Arneson CR, Ozcelik H, Redston M, Andrulis IL. P53 protein accumulation in non-invasive lesions surrounding p53 mutation positive invasive breast cancers. Breast Cancer Res. Treat. 2001;65(2):111–118
  8. Done SJ, Eskandarian S, Bull S, Redston M, Andrulis IL. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. J. Natl. Cancer Inst. 2001;93(9):700–704
  9. Elston EW, Ellis IO. Method for grading breast cancer. J. Clin. Pathol. 1993;46(2):189–190
  10. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 2000;77:81–137
  11. Ho GH, Calvano JE, Bisogna M, Borgen PI, Rosen PP, Tan LK, et al. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology. Cancer. 2000;89(11):2153–2160
  12. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin. Diagn. Pathol. 1994;11(3):167–180
  13. Hwang ES, DeVries S, Chew KL, Moore DH, Kerlikowske K, Thor A, et al. Patterns of chromosomal alterations in breast ductal carcinoma in situ. Clin. Cancer Res. 2004;10(15):5160–5167
  14. Kang JH, Kim SJ, Noh DY, Choe KJ, Lee ES, Kang HS. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer. J. Mol. Med. 2001;79(11):648–655
  15. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996;10(9):1054–1072
  16. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351(6326):453–456
  17. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, et al Gene expression profiles of human breast cancer progression. Proc. Natl. Acad. Sci. U.S.A. 2003;100(10):5974–5979
  18. Medina D, Kittrell FS, Shepard A, Contreras A, Rosen JM, Lydon J. Hormone dependence in premalignant mammary progression. Cancer Res. 2003;63(5):1067–1072
  19. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer Res. 2006;12(4):1157–1167
  20. Oren M. Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 1999;274(51):36031–36034
  21. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007;28(6):622–629
  22. Polyak K. Is breast tumor progression really linear?. Clin. Cancer Res. 2008;14(2):339–341
  23. Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin. Cancer Res. 2000;6(2):443–451
  24. Simpson JF, Page DL, Edgerton ME. p53 in Mammary ductal carcinoma in situ, mutations in high-grade lesions only?. J. Natl. Cancer Inst. 2001;93(9):666–667
  25. Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst. 1996;88(3–4):173–182
  26. Vousden KH. p53: death star. Cell. 2000;103(5):691–694
  27. Vousden KH, Lane DP. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007;8(4):275–283

PII: S1574-7891(09)00048-9

doi: 10.1016/j.molonc.2009.03.001

Molecular Oncology
Volume 3, Issue 3 , Pages 214-219 , June 2009

Article Tools